← Back to headlines
Abivax Launches $600M Public Offering
Biopharmaceutical company Abivax has commenced an underwritten public offering aiming to raise $600 million, seeking to secure capital for its ongoing research and development initiatives.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
